Current methods to study angiogenesis in cancer growth and development can be difficult and costly, requiring extensive use of in vivo methodologies. Here, we utilized an in vitro adipocyte derived stem cell and endothelial colony forming cell (ADSC/ECFC) co-culture system to investigate the effect of lentiviral-driven shRNA knockdown of target genes compared to a non-targeting shRNA control on cord formation using High Content Imaging. Cord formation was significantly reduced following knockdown of the VEGF receptor VEGFR2 in VEGF-driven cord formation and the FGF receptor FGFR1 in basic FGF (bFGF)-driven cord formation. In addition, cord formation was signifcantly reduced following knockdown of the transcription factor forkhead box protein O1 (FOXO1), a protein with known positive effects on angiogenesis and blood vessel stabilization in VEGF- and bFGF-driven cord formation. Lentiviral shRNA also demonstrated utility for stable knockdown of VEGFR2 and FOXO1 in ECFCs, allowing for interrogation of protein knockdown effects on in vivo neoangiogenesis in a Matrigel plug assay. In addition to interrogating the effect of gene knockdown in endothelial cells, we utilized lentiviral shRNA to knockdown specificity protein 1 (SP1), a transcription factor involved in the expression of VEGF, in U-87 MG tumor cells to demonstrate the ability to analyze angiogenesis in vitro in a tumor-driven transwell cord formation system and in tumor angiogenesis in vivo. A significant reduction in tumor-driven cord formation, VEGF secretion, and in vivo tumor angiogenesis was observed upon SP1 knockdown. Therefore, evaluation of target gene knockdown effects in the in vitro co-culture cord formation assay in the ADSC/ECFC co-culture, ECFCs alone, and in tumor cells translated directly to in vivo results, indicating the in vitro method as a robust, cost-effective and efficient in vitro surrogate assay to investigate target gene involvement in endothelial or tumor cell function in angiogenesis.
References
[1]
Kebers F, Lewalle JM, Desreux J, Munaut C, Devy L, et al. (1998) Induction of endothelial cell apoptosis by solid tumor cells. Exp Cell Res 240: 197–205. doi: 10.1006/excr.1998.3935
[2]
Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, et al. (1999) An in vitro model of angiogenesis: basic features. Angiogenesis 3: 335–344.
[3]
Merfeld-Clauss S, Gollahalli N, March KL, Traktuev DO (2010) Adipose tissue progenitor cells directly interact with endothelial cells to induce vascular network formation. Tissue Eng Part A 16: 2953–2966. doi: 10.1089/ten.tea.2009.0635
[4]
Chen Y, Wei T, Yan L, Lawrence F, Qian HR, et al. (2008) Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model. BMC Genomics 9: 264. doi: 10.1186/1471-2164-9-264
[5]
Jih YJ, Lien WH, Tsai WC, Yang GW, Li C, et al. (2001) Distinct regulation of genes by bFGF and VEGF-A in endothelial cells. Angiogenesis 4: 313–321.
[6]
McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5 Suppl 13–10. doi: 10.1634/theoncologist.5-suppl_1-3
[7]
Klagsbrun M, Moses MA (1999) Molecular angiogenesis. Chem Biol 6: R217–224. doi: 10.1016/s1074-5521(99)80081-7
[8]
Gyanchandani R, Kim S (2013) Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal. Clin Cancer Res.
[9]
Stachowiak MK, Moffett J, Joy A, Puchacz E, Florkiewicz R, et al. (1994) Regulation of bFGF gene expression and subcellular distribution of bFGF protein in adrenal medullary cells. J Cell Biol 127: 203–223. doi: 10.1083/jcb.127.1.203
[10]
Bagri A, Kouros-Mehr H, Leong KG, Plowman GD (2010) Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends Mol Med 16: 122–132. doi: 10.1016/j.molmed.2010.01.004
[11]
Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, et al. (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468: 829–833. doi: 10.1038/nature09624
[12]
Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, et al. (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468: 824–828. doi: 10.1038/nature09557
[13]
Yan W, Bentley B, Shao R (2008) Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol Biol Cell 19: 2278–2288. doi: 10.1091/mbc.e07-10-1068
[14]
Klagsbrun M (1991) Regulators of angiogenesis: stimulators, inhibitors, and extracellular matrix. J Cell Biochem 47: 199–200. doi: 10.1002/jcb.240470302
[15]
Daly C, Wong V, Burova E, Wei Y, Zabski S, et al. (2004) Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev 18: 1060–1071. doi: 10.1101/gad.1189704
[16]
Oellerich MF, Potente M (2012) FOXOs and sirtuins in vascular growth, maintenance, and aging. Circ Res 110: 1238–1251. doi: 10.1161/circresaha.111.246488
[17]
Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, et al. (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61: 4143–4154.
[18]
Tate C, Blosser W, Wyss L, Evans G, Xue Q, et al.. (2013) LY2228820 dimesylate, a Selective Inhibitor of p38 Mitogen-Activated Protein Kinase, Reduces Angiogenic Endothelial Cord Formation in vitro and in vivo. J Biol Chem.
[19]
Falcon BL, O′Clair B, McClure D, Evans GF, Stewart J, et al. (2013) Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition. J Hematol Oncol 6: 31. doi: 10.1186/1756-8722-6-31
[20]
Meier T, Uhlik M, Chintharlapalli S, Dowless M, Van Horn R, et al. (2011) Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Mol Cancer Ther 10: 2168–2178. doi: 10.1158/1535-7163.mct-11-0323
[21]
Low J, Blosser W, Dowless M, Ricci-Vitiani L, Pallini R, et al. (2012) Knockdown of ubiquitin ligases in glioblastoma cancer stem cells leads to cell death and differentiation. J Biomol Screen 17: 152–162. doi: 10.1177/1087057111422565
[22]
Bernatchez PN, Soker S, Sirois MG (1999) Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem 274: 31047–31054. doi: 10.1074/jbc.274.43.31047
[23]
Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576–579. doi: 10.1038/367576a0
[24]
Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4–25. doi: 10.1210/edrv.18.1.0287
[25]
Murakami M, Nguyen LT, Zhuang ZW, Moodie KL, Carmeliet P, et al. (2008) The FGF system has a key role in regulating vascular integrity. J Clin Invest 118: 3355–3366. doi: 10.1172/jci35298
[26]
Tiong KH, Mah LY, Leong CO (2013) Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis.
[27]
Hosaka T, Biggs WH 3rd, Tieu D, Boyer AD, Varki NM, et al. (2004) Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A 101: 2975–2980. doi: 10.1073/pnas.0400093101
[28]
Furuyama T, Kitayama K, Shimoda Y, Ogawa M, Sone K, et al. (2004) Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem 279: 34741–34749. doi: 10.1074/jbc.m314214200
[29]
Sigma website. Available: http://www.sigmaaldrich.com. Accessed 2012 Nov 1.
[30]
Claesson-Welsh L, Welsh M (2013) VEGFA and tumour angiogenesis. J Intern Med 273: 114–127. doi: 10.1111/joim.12019
[31]
Majeti BK, Lee JH, Simmons BH, Shojaei F (2013) VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer 13: 213. doi: 10.1186/1471-2407-13-213
[32]
Riely GJ, Miller VA (2007) Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res 13: s4623–4627. doi: 10.1158/1078-0432.ccr-07-0544
[33]
Roskoski R Jr (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356: 323–328. doi: 10.1016/j.bbrc.2007.02.156
[34]
Plate KH, Scholz A, Dumont DJ (2012) Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol 124: 763–775. doi: 10.1007/s00401-012-1066-5
[35]
Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, et al. (2004) Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 15: 4841–4853. doi: 10.1091/mbc.e04-05-0374
[36]
Wang L, Guan X, Gong W, Yao J, Peng Z, et al. (2005) Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis 22: 205–213. doi: 10.1007/s10585-005-5684-3
[37]
Deacon K, Onion D, Kumari R, Watson SA, Knox AJ (2012) Elevated SP-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer. J Biol Chem 287: 39967–39981. doi: 10.1074/jbc.m112.397042
[38]
Huang C, Xie K (2012) Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev 23: 25–35. doi: 10.1016/j.cytogfr.2012.01.003
[39]
Willard MD, Lajiness ME, Wulur IH, Feng B, Swearingen ML, et al. (2012) Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes. Mol Cancer Res 10: 739–749. doi: 10.1158/1541-7786.mcr-11-0483
